Compare HSBC Holdings plc (HSBC) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HSBC Holdings plc vs Incyte Corporation — how do they compare? HSBC Holdings plc trades at $92.98 (market cap $311.92B), while Incyte Corporation trades at $112.79 (market cap $22.85B). The key difference: HSBC Holdings plc is far larger — about 13.7× Incyte Corporation's market cap, and HSBC Holdings plc pays a 4.05% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold HSBC Holdings plc for 36 Days and Incyte Corporation for 33 Days on average.
| HSBC | INCY | |
|---|---|---|
Market Cap | $311.92B | $22.85B |
Volume | 3,546,658 | 1,927,029 |
Sector | Financials | Health |
52-Week High | $107.86 | $129.93 |
52-Week Low | $65.67 | $83.80 |
Typical Hold Time | 36 Days | 33 Days |
Enterprise Value | $222.19B | $18.35B |
Dividend Yield | 4.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HSBC trades at $92.61, down 1.17% over the past 24 hours, with technical indicators signaling a bearish trend. The company reported strong profitability with a net income margin of 34.54% and a P/E ratio of 13.23, reflecting reasonable valuation. Recent developments include expansion in technology banking and wealth management services, alongside strategic exits from non-core markets like Germany.
The outlook for HSBC is mixed; growth in wealth management and Asia presents opportunities, but bearish technicals and CFO transition in 2027 pose risks. Analyst sentiment is cautious with a majority hold rating, emphasizing the need for execution on strategic priorities to drive shareholder value amid global economic uncertainties.
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
